Exact Mass: 319.0949708

Exact Mass Matches: 319.0949708

Found 17 metabolites which its exact mass value is equals to given mass value 319.0949708, within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error 0.0002 dalton.

Benzamil

3,5-diamino-N-(N-benzylcarbamimidoyl)-6-chloropyrazine-2-carboxamide

C13H14ClN7O (319.0948304)


   

Ibandronate

{1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid

C9H23NO7P2 (319.0949708)


Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures. M - Musculo-skeletal system > M05 - Drugs for treatment of bone diseases > M05B - Drugs affecting bone structure and mineralization > M05BA - Bisphosphonates C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates

   
   
   
   
   

2-(3,4-dihydro-2-methoxy-4-oxoquinazolinyl)-1H-indole-3-carboxaldehyde|orirenierine B

2-(3,4-dihydro-2-methoxy-4-oxoquinazolinyl)-1H-indole-3-carboxaldehyde|orirenierine B

C18H13N3O3 (319.09568680000007)


   

Ibandronate

Ibandronate sodium;Ibandronate sodium monohydrate;Ibandronic Acid;R484

C9H23NO7P2 (319.0949708)


M - Musculo-skeletal system > M05 - Drugs for treatment of bone diseases > M05B - Drugs affecting bone structure and mineralization > M05BA - Bisphosphonates C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates

   

N-(2,3-Dihydro-2-oxo-1H-benzimidazol-5-yl)-3-hydroxy-2-naphthalenecarboxamide

N-(2,3-Dihydro-2-oxo-1H-benzimidazol-5-yl)-3-hydroxy-2-naphthalenecarboxamide

C18H13N3O3 (319.09568680000007)


   

ibandronic acid

ibandronic acid

C9H23NO7P2 (319.0949708)


M - Musculo-skeletal system > M05 - Drugs for treatment of bone diseases > M05B - Drugs affecting bone structure and mineralization > M05BA - Bisphosphonates C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates

   

N-(1,3-benzodioxol-5-ylmethyl)-4-benzofuro[3,2-d]pyrimidinamine

N-(1,3-benzodioxol-5-ylmethyl)-4-benzofuro[3,2-d]pyrimidinamine

C18H13N3O3 (319.09568680000007)


   
   

18,19-dihydroxy-3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2(10),4,6,8,15,17,19-octaen-14-one

18,19-dihydroxy-3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2(10),4,6,8,15,17,19-octaen-14-one

C18H13N3O3 (319.09568680000007)


   

4-benzyl-3-hydroxy-4h-pyrazino[2,1-b]quinazoline-1,6-dione

4-benzyl-3-hydroxy-4h-pyrazino[2,1-b]quinazoline-1,6-dione

C18H13N3O3 (319.09568680000007)


   

(11s,12r)-11,12-dihydroxy-3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2(10),4,6,8,15,17,19-octaen-14-one

(11s,12r)-11,12-dihydroxy-3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2(10),4,6,8,15,17,19-octaen-14-one

C18H13N3O3 (319.09568680000007)


   

(4s)-4-benzyl-3-hydroxy-4h-pyrazino[2,1-b]quinazoline-1,6-dione

(4s)-4-benzyl-3-hydroxy-4h-pyrazino[2,1-b]quinazoline-1,6-dione

C18H13N3O3 (319.09568680000007)


   

11,12-dihydroxy-3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2(10),4,6,8,15,17,19-octaen-14-one

11,12-dihydroxy-3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2(10),4,6,8,15,17,19-octaen-14-one

C18H13N3O3 (319.09568680000007)